BioSpace News Archive

Aeglea BioTherapeutics, Inc. announced that the compensation committee of its board of directors has granted non-qualified stock options to purchase an aggregate of 1,884,838 shares of Aeglea’s common stock to Jeffrey M. Goldberg as a material inducement to his appointment as the chief executive officer of Aeglea in accordance with Rule 5635 of the Nasdaq Listing Rules.

Cullinan Oncology, Inc., a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, announced that the compensation committee of the Company’s Board of Directors granted stock option awards to purchase an aggregate of 86,000 shares of its common stock to three employees outside Cullinan Oncology, Inc’s 2021 Stock Option and Incentive Plan.